Literature DB >> 18665325

Abatacept and serious respiratory infections in patients with previous lung disease.

Karla L Miller1, Allen D Sawitzke, John Doane.   

Abstract

Abatacept is a biologic agent used in the treatment of rheumatoid arthritis, for which underlying chronic obstructive lung disease is listed as a precaution to its use due to concern for increased risk of respiratory adverse events. We describe two cases of severe respiratory complications affecting rheumatoid arthritis patients undergoing treatment with abatacept who had been previously diagnosed with underlying lung disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18665325     DOI: 10.1007/s10067-008-0979-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

Review 1.  Sulphasalazine and lung toxicity.

Authors:  S D Parry; C Barbatzas; E T Peel; J R Barton
Journal:  Eur Respir J       Date:  2002-04       Impact factor: 16.671

2.  Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

Authors:  M Weinblatt; B Combe; A Covucci; R Aranda; J C Becker; E Keystone
Journal:  Arthritis Rheum       Date:  2006-09

3.  Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis.

Authors:  Christian Zimmer; Martin Beiderlinden; Jürgen Peters
Journal:  Clin Rheumatol       Date:  2005-10-01       Impact factor: 2.980

4.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Authors:  Joel M Kremer; Maxime Dougados; Paul Emery; Patrick Durez; Jean Sibilia; William Shergy; Serge Steinfeld; Elizabeth Tindall; Jean-Claude Becker; Tracy Li; Isaac F Nuamah; Richard Aranda; Larry W Moreland
Journal:  Arthritis Rheum       Date:  2005-08

5.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Authors:  Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

6.  Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers.

Authors:  B W M Willemse; N H T ten Hacken; B Rutgers; I G A T Lesman-Leegte; D S Postma; W Timens
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

7.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K Watson; M Lunt; K L Hyrich; A J Silman; D P M Symmons
Journal:  Arthritis Rheum       Date:  2006-08

Review 8.  Methotrexate pulmonary toxicity.

Authors:  G W Cannon
Journal:  Rheum Dis Clin North Am       Date:  1997-11       Impact factor: 2.670

Review 9.  Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease.

Authors:  Ashwin N Ananthakrishnan; Tan Attila; Mary F Otterson; Randolph J Lipchik; Benson T Massey; Richard A Komorowski; David G Binion
Journal:  J Clin Gastroenterol       Date:  2007-08       Impact factor: 3.062

10.  Cigarette smoking and upper respiratory infection among recruits in basic combat training.

Authors:  G H Blake; T D Abell; W G Stanley
Journal:  Ann Intern Med       Date:  1988-08-01       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.